The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

Epidermal growth factor receptor non-small cell lung cancer (EGFR NSCLC) is a lung cancer subtype driven by EGFR gene mutations, leading to rapid tumor growth. It's prevalent particularly in Asian ...

Giovanna Prout joins Countable Labs as CEO to accelerate commercialization of Countable Labs’ products Countable Labs, the developer of Countable PCR, a category-defining PCR technology that sets a ...

Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...

Overview of Epigenetics MarketThe global Epigenetics Market is valued at USD 2.56 Billion in 2024 and is projected to reach a value of USD 9.11 Billion by 2035 at a CAGR (Compound Annual Growth Rate) ...

Q3 2025 Management View CEO Anthony Zook highlighted record clinical volumes and revenues for the third quarter of 2025, emphasizing the company’s progress in next-generation sequencing (NGS) and ...

NeoGenomics reaffirmed its full-year 2025 guidance, projecting revenue between $720 million and $726 million, representing 9-10% growth from fiscal 2024. The company expects a net loss between $108 ...

"These results are encouraging, highlighting TET2-mutated clonal hematopoiesis as a potential biomarker to select patients who are more likely to respond to immunotherapy," said Padmanee Sharma, M.D., ...

Twist Bioscience is advancing synthetic DNA manufacturing with innovation but remains at the lower end of its 52-week range.

The company's multi-year strategy involves the rollout of new products and upgrades to existing ones that further strengthen its position.

Illumina is rated a BUY as it drives growth with AI, multiomics, and strategic acquisitions. Click here to read my earnings ...